Drug intelligence / Profile preview

Bufei Huatan granule

Development stage: Phase 3
Lead developer: Henan University of Chinese Medicine
Administration: Oral

Overview

Bufei Huatan is a Traditional Chinese Medicine (TCM) granule formulation developed by the Henan University of Chinese Medicine for the treatment of clinically stable bronchiectasis. The formula is designed based on TCM principles to tonify the lung (Bufei) and resolve phlegm (Huatan), specifically targeting the underlying Lung-Spleen Qi Deficiency and Phlegm-Dampness syndromes common in chronic respiratory diseases. It is typically used as a maintenance therapy to stabilize the airway environment and reduce the frequency of acute exacerbations. In clinical trials, it is often evaluated alongside or compared with other TCM formulations like Yifei Qinghua, depending on the patient's specific syndrome differentiation.

Other names: Bufei HuatanBufei Huatan formula

Beyond the preview

Go deeper on Bufei Huatan granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bufei Huatan granule.

Explore the full profile